[go: up one dir, main page]

RS64039B1 - Metode i kompozicije za lečenje poremećaja povezanih sa komplementom - Google Patents

Metode i kompozicije za lečenje poremećaja povezanih sa komplementom

Info

Publication number
RS64039B1
RS64039B1 RS20230196A RSP20230196A RS64039B1 RS 64039 B1 RS64039 B1 RS 64039B1 RS 20230196 A RS20230196 A RS 20230196A RS P20230196 A RSP20230196 A RS P20230196A RS 64039 B1 RS64039 B1 RS 64039B1
Authority
RS
Serbia
Prior art keywords
compositions
treatment
methods
related disorders
complement related
Prior art date
Application number
RS20230196A
Other languages
English (en)
Inventor
Russell P Rother
Camille Bedrosian
Stephen P Squinto
Leonard Bell
Original Assignee
Alexion Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42153320&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS64039(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alexion Pharma Inc filed Critical Alexion Pharma Inc
Publication of RS64039B1 publication Critical patent/RS64039B1/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
RS20230196A 2008-11-10 2009-11-10 Metode i kompozicije za lečenje poremećaja povezanih sa komplementom RS64039B1 (sr)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US19880308P 2008-11-10 2008-11-10
US19956908P 2008-11-18 2008-11-18
US19956308P 2008-11-18 2008-11-18
US19956208P 2008-11-18 2008-11-18
US19976408P 2008-11-19 2008-11-19
US20063408P 2008-12-01 2008-12-01
US20063508P 2008-12-01 2008-12-01
US20064008P 2008-12-01 2008-12-01
US18178809P 2009-05-28 2009-05-28
US22804709P 2009-07-23 2009-07-23
EP15152757.9A EP2894165B1 (en) 2008-11-10 2009-11-10 Methods and compositions for treating complement-associated disorders

Publications (1)

Publication Number Publication Date
RS64039B1 true RS64039B1 (sr) 2023-04-28

Family

ID=42153320

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20230196A RS64039B1 (sr) 2008-11-10 2009-11-10 Metode i kompozicije za lečenje poremećaja povezanih sa komplementom

Country Status (21)

Country Link
US (9) US9447176B2 (sr)
EP (6) EP2894165B1 (sr)
JP (8) JP6223659B2 (sr)
KR (1) KR20110094029A (sr)
CN (3) CN109045296A (sr)
AU (1) AU2009313203B2 (sr)
BR (1) BRPI0921237A2 (sr)
CA (2) CA2742802C (sr)
DK (1) DK2894165T5 (sr)
ES (1) ES2940466T3 (sr)
FI (1) FI2894165T3 (sr)
HR (1) HRP20230167T1 (sr)
HU (1) HUE061548T2 (sr)
LT (1) LT2894165T (sr)
NZ (3) NZ614351A (sr)
PL (1) PL2894165T3 (sr)
PT (1) PT2894165T (sr)
RS (1) RS64039B1 (sr)
SI (1) SI2894165T1 (sr)
SM (1) SMT202300082T1 (sr)
WO (1) WO2010054403A1 (sr)

Families Citing this family (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9415102B2 (en) 2002-09-06 2016-08-16 Alexion Pharmaceuticals, Inc. High concentration formulations of anti-C5 antibodies
US20050271660A1 (en) 2002-09-06 2005-12-08 Alexion Pharmaceuticals, Inc. Nebulization of monoclonal antibodies for treating pulmonary diseases
US8840893B2 (en) 2004-06-10 2014-09-23 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
CA2647846C (en) 2006-03-31 2016-06-21 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
JP2010505946A (ja) 2006-10-10 2010-02-25 アカデミシュ ジーケンハウス ビイ デ ユニヴェアズィテート ファン アムステルダム 神経再生改善のための補体阻害
CN101874042B9 (zh) 2007-09-26 2019-01-01 中外制药株式会社 利用cdr的氨基酸取代来改变抗体等电点的方法
BRPI0911431B8 (pt) 2008-04-11 2021-05-25 Chugai Pharmaceutical Co Ltd composição farmacêutica compreendendo um antígeno e método para aumentar o número de antígenos que podem ser ligados por um anticorpo
CA2742802C (en) 2008-11-10 2019-11-26 Alexion Pharmaceuticals, Inc. Methods and compositions for treating complement-associated disorders
EP3508477B1 (en) 2008-12-22 2021-11-10 ChemoCentryx, Inc. C5ar antagonists
KR20120105405A (ko) * 2009-06-23 2012-09-25 알렉시온 파마슈티칼스, 인코포레이티드 보체 단백질에 결합하는 이중특이적 항체
ES2615732T3 (es) * 2010-03-01 2017-06-08 Alexion Pharmaceuticals, Inc. Composiciones para tratar la enfermedad de Degos
ES2552954T3 (es) 2010-04-30 2015-12-03 Alexion Pharmaceuticals, Inc. Anticuerpos anti-C5a y métodos para el uso de los anticuerpos
DK2585064T3 (en) 2010-06-24 2017-07-24 Chemocentryx Inc C5aR antagonists
WO2012037370A1 (en) * 2010-09-15 2012-03-22 Celldex Therapeutics, Inc. Treatment of chronic nephropathies using soluble complement receptor type i (scr1)
JP6030452B2 (ja) 2010-11-30 2016-11-24 中外製薬株式会社 複数分子の抗原に繰り返し結合する抗原結合分子
US20150166676A1 (en) * 2011-04-08 2015-06-18 Omeros Corporation Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation
NZ617298A (en) * 2011-04-08 2015-08-28 Univ Leicester Methods for treating conditions associated with masp-2 dependent complement activation
US9644035B2 (en) 2011-04-08 2017-05-09 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
CN103796667A (zh) 2011-06-22 2014-05-14 艾普莱斯制药公司 用补体抑制剂治疗慢性障碍的方法
CA2863862C (en) 2012-02-20 2021-03-16 Swedish Orphan Biovitrum Ab (Publ) Polypeptides binding to human complement c5
CN104205155A (zh) * 2012-03-16 2014-12-10 亚力克恩制药公司 给接受补体抑制剂的患者分配补体抑制药物的方法
LT2861246T (lt) * 2012-06-18 2021-04-26 Omeros Corporation Masp-1 ir (arba) masp-2, ir (arba) masp-3 slopinimo kompozicijos ir būdai, skirti įvairių ligų ir sutrikimų gydymui
US9926366B2 (en) 2012-10-04 2018-03-27 Novelmed Therapeutics, Inc. Methods of treating a hemolytic disorder comprising administering anti-properdin antibodies
EP3722320A3 (en) 2012-10-25 2020-12-30 Bioverativ USA Inc. Anti-complement c1s antibodies and uses thereof
WO2014071206A1 (en) 2012-11-02 2014-05-08 True North Therapeutics, Inc. Anti-complement c1s antibodies and uses thereof
WO2014078622A1 (en) * 2012-11-15 2014-05-22 The Brigham And Women's Hospital, Inc. Method and system for diagnosing and treating preeclampsia
WO2014110438A1 (en) * 2013-01-11 2014-07-17 Alexion Pharmaceuticals, Inc. Compounds and methods related to the c5d domain of complement component c5
RU2663349C2 (ru) * 2013-01-31 2018-08-03 СЕУЛ НЭШНЛ ЮНИВЕРСИТИ Ар энд ДиБи ФАУНДЕЙШН Антитело против с5 и способ предупреждения и лечения обусловленных комплементом заболеваний
BR112015022876B1 (pt) 2013-03-14 2022-03-15 Alnylam Pharmaceuticals, Inc Agente de rna fita dupla, composição farmacêutica e método para inibição da expressão do componente do complemento c5 em uma célula
PT2968457T (pt) * 2013-03-14 2018-11-07 Baxalta Inc Fator h para transplante
CA2897334A1 (en) 2013-03-29 2014-10-02 Alexion Pharmaceuticals, Inc. Compositions and methods for increasing the serum half-life of a therapeutic agent targeting complement c5
CA2918959C (en) * 2013-08-07 2024-05-07 Alexion Pharmaceuticals, Inc. Atypical hemolytic uremic syndrome biomarker proteins
WO2015023972A1 (en) * 2013-08-16 2015-02-19 Alexion Pharmaceuticals, Inc. Treatment of graft rejection by administering a complement inhibitor to an organ prior to transplant
CA2921856A1 (en) * 2013-09-16 2015-03-19 Children's Hospital Medical Center Compositions and methods for treatment of hsct-associated thrombotic microangiopathy
EP3750919A1 (en) * 2013-10-17 2020-12-16 Omeros Corporation Methods for treating conditions associated with masp-2 dependent complement activation
CA3107872A1 (en) 2013-12-12 2015-06-18 Alnylam Pharmaceuticals, Inc. Complement component irna compositions and methods of use thereof
RU2693430C2 (ru) * 2014-02-20 2019-07-02 Аллерган, Инк. Антитела к компоненту комплемента с5
CN114716544B (zh) * 2014-02-26 2024-10-01 阿勒根公司 补体组分c5抗体
NZ631007A (en) * 2014-03-07 2015-10-30 Alexion Pharma Inc Anti-c5 antibodies having improved pharmacokinetics
US10155983B2 (en) 2014-03-31 2018-12-18 Machaon Diagnostics, Inc. Method of diagnosis of complement-mediated thrombotic microangiopathies
RS59353B1 (sr) 2014-06-12 2019-10-31 Ra Pharmaceuticals Inc Modulacija aktivnosti komplementa
WO2016040589A1 (en) * 2014-09-12 2016-03-17 Alnylam Pharmaceuticals, Inc. Polynucleotide agents targeting complement component c5 and methods of use thereof
MX368492B (es) 2014-09-29 2019-10-04 Chemocentryx Inc Procesos e compuestos intermedios en la preparacion de antagonistas de c5ar.
WO2016081314A1 (en) 2014-11-17 2016-05-26 Alexion Pharmaceuticals, Inc. Risk evaluation and management strategy involving patient follow-ups relating to a complement inhibitor
US20160168237A1 (en) * 2014-12-12 2016-06-16 Alexion Pharmaceuticals, Inc. Method for treating a complement mediated disorder caused by an infectious agent in a patient
CA2967554A1 (en) 2014-12-19 2016-06-23 Yoshinao Ruike Anti-c5 antibodies and methods of use
KR102650420B1 (ko) 2014-12-19 2024-03-21 추가이 세이야쿠 가부시키가이샤 항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법
WO2016117346A1 (en) 2015-01-22 2016-07-28 Chugai Seiyaku Kabushiki Kaisha A combination of two or more anti-c5 antibodies and methods of use
HRP20211824T1 (hr) 2015-01-28 2022-03-04 Ra Pharmaceuticals, Inc. Modulatori aktivnosti komplementa
FI3280440T3 (fi) 2015-04-06 2023-03-09 Bioverativ Usa Inc Humanisoituja anti-c1s-vasta-aineita ja niiden käyttömenetelmiä
US20180311299A1 (en) * 2015-05-01 2018-11-01 Alexion Pharmaceuticals, Inc. Efficacy of an anti-c5 antibody in the prevention of antibody mediated rejection in sensitized recipients of a kidney transplant
WO2016200627A1 (en) 2015-06-09 2016-12-15 Children's Hospital Medical Center Dosing algorithm for complement inhibitor
WO2016201301A1 (en) 2015-06-12 2016-12-15 Alnylam Pharmaceuticals, Inc. Complement component c5 irna compositions and methods of use thereof
WO2017048495A1 (en) 2015-09-14 2017-03-23 Children's Hospital Medical Center Methods and compositions for treatment of gaucher disease via modulation of c5a receptor
ES2986888T3 (es) * 2015-10-30 2024-11-13 Alexion Pharma Inc Un método para inhibir las exacerbaciones de la vasculopatía del aloinjerto mediada por células T
CN108697759B (zh) 2015-12-16 2022-08-02 Ra制药公司 补体活性的调节剂
WO2017109208A1 (en) * 2015-12-23 2017-06-29 Albert-Ludwigs-Universität Freiburg Polypeptides for inhibiting complement activation
JP7339733B2 (ja) * 2016-01-14 2023-09-06 ケモセントリックス，インコーポレイティド Ｃ３腎症を処置する方法
EP3454902A4 (en) * 2016-05-10 2019-10-09 Annexon, Inc. ANTI-COMPLEMENT FACTOR C4 / C4B ANTIBODIES AND USES THEREOF
JP2019517473A (ja) * 2016-05-27 2019-06-24 アレクシオン ファーマシューティカルズ インコーポレイテッドＡｌｅｘｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 難治性全身型重症筋無力症の処置のための方法
EP3463459A1 (en) * 2016-06-07 2019-04-10 Novartis AG Tesidolumab for use in the treatment of transplant rejection
EP3463460A1 (en) * 2016-06-07 2019-04-10 Novartis AG An anti-c5 antibody dosing regimen
WO2017212375A1 (en) * 2016-06-07 2017-12-14 Novartis Ag Anti-c5 antibody for treating patients with complement c5 polymorphism
US20190256845A1 (en) 2016-06-10 2019-08-22 Alnylam Pharmaceuticals, Inc. COMPLEMENT COMPONENT C5 iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)
SG10202012243VA (en) 2016-06-14 2021-01-28 Regeneron Pharma Anti-c5 antibodies and uses thereof
CN109689099B (zh) 2016-08-05 2023-02-28 中外制药株式会社 用于预防或治疗il-8相关疾病的组合物
US20200057046A1 (en) 2016-10-27 2020-02-20 Alexion Pharmaceuticals, Inc. Assay for c5b-9 deposition in complement-associated disorders
WO2018106859A1 (en) 2016-12-07 2018-06-14 Ra Pharmaceuticals, Inc. Modulators of complement activity
MX2019007749A (es) 2017-01-31 2019-09-09 Chugai Pharmaceutical Co Ltd Composicion farmaceutica para usarse en el tratamiento o prevencion de una enfermedad relacionada con c5 y metodo para tratar o prevenir una enfermedad relacionada con c5.
IL268748B2 (en) * 2017-02-27 2025-01-01 Regeneron Pharma Human model of kidney and liver disorders
SG11201908238SA (en) * 2017-03-06 2019-10-30 The Trustees Of The Univ Of Pensylvania Anti-c5 antibodies and uses thereof
JP7194698B2 (ja) * 2017-05-22 2022-12-22 アレクシオン ファーマシューティカルズ， インコーポレイテッド 患者においてタンパク質漏出性腸症を処置するための抗ｃ５抗体の投薬量および投与
EP4218813A3 (en) 2017-07-27 2023-08-16 Alexion Pharmaceuticals, Inc. High concentration anti-c5 antibody formulations
JP2020536097A (ja) * 2017-10-04 2020-12-10 アレクシオン ファーマシューティカルズ， インコーポレイテッド 膜性増殖性糸球体腎炎患者の処置のための抗ｃ５抗体の投薬量および投与
CA3080187A1 (en) 2017-10-26 2019-05-02 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh) and atypical hemolytic uremic syndrome (ahus)
CA3078971A1 (en) 2017-11-01 2019-05-09 Alnylam Pharmaceuticals, Inc. Complement component c3 irna compositions and methods of use thereof
MX2020005142A (es) 2017-11-16 2021-01-15 Iveric Bio Inc Un método para tratar o prevenir la vasculopatía coroidal polipoidal idiopática (ipcv).
RU2657768C1 (ru) * 2017-11-23 2018-06-15 Елена Вячеславовна Волкова Способ лечения беременных с преэклампсией средней тяжести
EP3717916B1 (en) 2017-11-29 2025-01-01 F. Hoffmann-La Roche AG Target interference suppressed anti-drug antibody assay
US12037389B2 (en) 2017-12-01 2024-07-16 Children's Hospital Medical Center Compositions for interferon blockade and methods of using same
KR20200095485A (ko) 2017-12-04 2020-08-10 라 파마슈티컬스 인코포레이티드 보체 활성의 조절인자
SG11202004662RA (en) 2017-12-13 2020-06-29 Regeneron Pharma Anti-c5 antibody combinations and uses thereof
GB201800620D0 (en) 2018-01-15 2018-02-28 Univ Manchester C3b Binding Polypeptide
US20190247560A1 (en) * 2018-02-13 2019-08-15 Gambro Lundia Ab Extracorporeal devices and methods of treating complement factor related diseases
WO2020027279A1 (en) 2018-08-01 2020-02-06 Chugai Seiyaku Kabushiki Kaisha A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease
CA3111396A1 (en) 2018-09-06 2020-03-12 The Trustees Of The University Of Pennsylvania Humanized anti-c5 antibodies and uses thereof
WO2020060987A1 (en) * 2018-09-18 2020-03-26 Alnylam Pharmaceuticals, Inc. Complement component c5 irna compositions and methods of use
BR112021008063A2 (pt) 2018-10-30 2021-08-10 Alexion Pharmaceuticals, Inc. dosagem subcutânea e administração de anticorpos anti-c 5 para tratamento de hemoglobinúria paroxística noturna (pnh)
CA3131927A1 (en) 2019-03-08 2020-09-17 Ra Pharmaceuticals, Inc. Modulators of complement activity
TW202102481A (zh) 2019-03-29 2021-01-16 美商Ｒａ製藥公司 補體調節劑和相關方法
CA3137895A1 (en) 2019-04-24 2020-10-29 Ra Pharmaceuticals, Inc. Compositions and methods for modulating complement activity
GB2584105B (en) * 2019-05-21 2023-08-02 Argenx Bvba Methods of treating neuropathy
KR20240001329A (ko) 2019-07-31 2024-01-03 에프. 호프만-라 로슈 아게 항-c5 항체 크로발리맙의 사용에 의한 c5-관련 질병의 치료 또는 예방을 위한 투여량 및 투여 섭생
TW202120125A (zh) 2019-07-31 2021-06-01 瑞士商赫孚孟拉羅股份公司 藉由使用抗c5抗體克羅伐單抗（crovalimab）之治療或預防c5相關疾病之劑量及投藥療程
WO2021154941A1 (en) 2020-01-31 2021-08-05 Alnylam Pharmaceuticals, Inc. Complement component c5 irna compositions for use in the treatment of amyotrophic lateral sclerosis (als)
AU2021294222A1 (en) 2020-06-16 2023-01-19 F. Hoffmann-La Roche Ag Method for determining the free antigen of an antibody in a sample
CA3220629A1 (en) 2021-05-28 2022-12-01 Tobin J. CAMMETT Methods for detecting cm-tma biomarkers
WO2023044370A2 (en) 2021-09-17 2023-03-23 Alnylam Pharmaceuticals, Inc. Irna compositions and methods for silencing complement component 3 (c3)
WO2024054436A1 (en) 2022-09-06 2024-03-14 Alexion Pharmaceuticals, Inc. Diagnostic and prognostic biomarker profiles in patients with hematopoietic stem cell transplant-associated thrombotic microangiopathy (hsct-tma)

Family Cites Families (122)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4634666A (en) 1984-01-06 1987-01-06 The Board Of Trustees Of The Leland Stanford Junior University Human-murine hybridoma fusion partner
US4686100A (en) 1985-04-02 1987-08-11 The Board Of Trustees Of The Leland Stanford Junior University Method for the treatment of adult respiratory distress syndrome
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
AU6131086A (en) 1985-07-05 1987-01-30 Whitehead Institute For Biomedical Research Epithelial cells expressing foreign genetic material
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4863457A (en) 1986-11-24 1989-09-05 Lee David A Drug delivery device
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US5116742A (en) 1986-12-03 1992-05-26 University Patents, Inc. RNA ribozyme restriction endoribonucleases and methods
WO1988006630A1 (en) 1987-03-02 1988-09-07 Genex Corporation Method for the preparation of binding molecules
JP3015383B2 (ja) 1987-09-11 2000-03-06 ホワイトヘツド・インスチチユート・フオー・バイオメデイカル・リサーチ 形質導入した線維芽およびそれらの使用
EP0391960B1 (en) 1987-12-11 1994-08-17 Whitehead Institute For Biomedical Research Genetic modification of endothelial cells
DE68927996T2 (de) 1988-02-05 1997-12-04 Hughes Howard Med Inst Modifizierte hepatozyten und deren anwendung
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5135916A (en) 1989-06-12 1992-08-04 Oklahoma Medical Research Foundation Inhibition of complement mediated inflammatory response
DE3924924A1 (de) 1989-07-27 1991-02-07 Goetze Otto Verfahren zum nachweis und/oder der quantitativen bestimmung von komplementpeptid c5a und/oder c5adesarg
US5164188A (en) 1989-11-22 1992-11-17 Visionex, Inc. Biodegradable ocular implants
US6657103B1 (en) 1990-01-12 2003-12-02 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1991010741A1 (en) 1990-01-12 1991-07-25 Cell Genesys, Inc. Generation of xenogeneic antibodies
US6713610B1 (en) 1990-01-12 2004-03-30 Raju Kucherlapati Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US20040010810A1 (en) 1990-01-12 2004-01-15 Abgenix, Inc. Generation of xenogeneic antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
GB9007971D0 (en) * 1990-04-09 1990-06-06 Imutran Ltd Pharmaceutical formulations
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
ATE352612T1 (de) 1990-08-29 2007-02-15 Pharming Intellectual Pty Bv Homologe rekombination in säugetier-zellen
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US7041871B1 (en) 1995-10-10 2006-05-09 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
WO1993012227A1 (en) 1991-12-17 1993-06-24 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
EP0814159B1 (en) 1990-08-29 2005-07-27 GenPharm International, Inc. Transgenic mice capable of producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
AU656544B2 (en) 1990-10-31 1995-02-09 Brigham And Women's Hospital Genetic modification of endothelial cells
KR0185215B1 (ko) 1990-11-30 1999-05-01 요시다 쇼오지 서방성 안구삽입용 약제
ATE164395T1 (de) 1990-12-03 1998-04-15 Genentech Inc Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
US5780279A (en) 1990-12-03 1998-07-14 Genentech, Inc. Method of selection of proteolytic cleavage sites by directed evolution and phagemid display
CA2097825A1 (en) * 1990-12-06 1992-06-07 Henry C. Marsh, Jr. Synergistic compositions of soluble complement receptors and compounds that inhibit complement and/or suppress immune activity
DK1279731T3 (da) 1991-03-01 2007-09-24 Dyax Corp Fremgangsmåde til udvikling af bindende miniproteiner
WO1992022670A1 (en) 1991-06-12 1992-12-23 Genpharm International, Inc. Early detection of transgenic embryos
WO1992022645A1 (en) 1991-06-14 1992-12-23 Genpharm International, Inc. Transgenic immunodeficient non-human animals
WO1993004169A1 (en) 1991-08-20 1993-03-04 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
WO1994000569A1 (en) 1992-06-18 1994-01-06 Genpharm International, Inc. Methods for producing transgenic non-human animals harboring a yeast artificial chromosome
ES2301158T3 (es) 1992-07-24 2008-06-16 Amgen Fremont Inc. Produccion de anticuerpos xenogenicos.
US5508717A (en) 1992-07-28 1996-04-16 Sony Corporation Computer pointing device with dynamic sensitivity
CA2155933C (en) 1993-02-12 2000-04-04 James L. Levin Pulmonary administration of scr1 and other complement inhibitory proteins
EP0754225A4 (en) 1993-04-26 2001-01-31 Genpharm Int HETEROLOGIC ANTIBODY-PRODUCING TRANSGENIC NON-HUMAN ANIMALS
US5625825A (en) 1993-10-21 1997-04-29 Lsi Logic Corporation Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network
CZ295827B6 (cs) 1994-03-07 2005-11-16 Nektar Therapeutics Způsob aerosolizace dávky inzulinu, inzulinový přípravek a jeho použití
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
US5643763A (en) 1994-11-04 1997-07-01 Genpharm International, Inc. Method for making recombinant yeast artificial chromosomes by minimizing diploid doubling during mating
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6019968A (en) 1995-04-14 2000-02-01 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
US20050287630A1 (en) 1995-04-27 2005-12-29 Abgenix, Inc. Human antibodies derived from immunized xenomice
CA2219486A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
ATE219517T1 (de) 1995-08-18 2002-07-15 Morphosys Ag Protein-/(poly)peptidbibliotheken
US20030143204A1 (en) 2001-07-27 2003-07-31 Lewis David L. Inhibition of RNA function by delivery of inhibitors to animal cells
EP2305027B1 (en) 1996-12-03 2014-07-02 Amgen Fremont Inc. Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom
AUPO755097A0 (en) 1997-06-25 1997-07-17 University Of Queensland, The Receptor agonist and antagonist
US7056897B2 (en) 1997-11-03 2006-06-06 The Arizona Board Of Regents Inducible expression vectors and methods of use thereof
ES2278463T3 (es) 1998-12-08 2007-08-01 Biovation Limited Metodo para reducir la inmunogenicidad de proteinas.
AU779869B2 (en) 1999-04-13 2005-02-17 Nektar Therapeutics Pulmonary administration of dry powder formulations for treating infertility
WO2000061178A1 (en) 1999-04-13 2000-10-19 Inhale Therapeutics Systems, Inc. Pulmonary administration of dry powder formulations for treating infertility
GB9910975D0 (en) 1999-05-13 1999-07-14 Univ Strathclyde Rapid dehydration of proteins
US6673346B1 (en) 1999-08-31 2004-01-06 The Regents Of The University Of Michigan Compositions and methods for the treatment of sepsis
US6794132B2 (en) 1999-10-02 2004-09-21 Biosite, Inc. Human antibodies
US6680209B1 (en) 1999-12-06 2004-01-20 Biosite, Incorporated Human antibodies as diagnostic reagents
AU2001234962A1 (en) * 2000-02-10 2001-08-20 Alexion Pharmaceuticals, Inc. Mixtures of caspase inhibitors and complement inhibitors and methods of use thereof
AU3400102A (en) 2000-12-05 2002-06-18 Alexion Pharma Inc Rationally designed antibodies
WO2002072636A2 (en) * 2000-12-28 2002-09-19 Altus Biologics Inc. Crystals of whole antibodies and fragments thereof and methods for making and using them
KR100899970B1 (ko) 2001-02-19 2009-05-28 메르크 파텐트 게엠베하 Ｔ-세포 에피토프의 동정 방법 및 감소된 면역원성을 갖는분자의 제조를 위한 용도
CA2448427C (en) 2001-06-01 2013-09-24 Biogen, Inc. Molecules and methods for inhibiting shedding of kim-1
US7393648B2 (en) 2001-12-03 2008-07-01 Alexion Pharmaceuticals, Inc. Hybrid antibodies
EP1572902B1 (en) 2002-02-01 2014-06-11 Life Technologies Corporation HIGH POTENCY siRNAS FOR REDUCING THE EXPRESSION OF TARGET GENES
WO2003081206A2 (en) 2002-03-18 2003-10-02 Alexion Pharmaceuticals, Inc. Stratification of patient populations having or suspected of having rheumatoid arthritis
US7556944B2 (en) 2002-05-03 2009-07-07 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for use in preparing siRNAs
WO2004015062A2 (en) 2002-08-12 2004-02-19 New England Biolabs, Inc. Methods and compositions relating to gene silencing
US20050271660A1 (en) 2002-09-06 2005-12-08 Alexion Pharmaceuticals, Inc. Nebulization of monoclonal antibodies for treating pulmonary diseases
EP1545611B1 (en) 2002-09-06 2016-11-09 Alexion Pharmaceuticals, Inc. Method of treatment of asthma using antibodies to complement component c5
US9415102B2 (en) * 2002-09-06 2016-08-16 Alexion Pharmaceuticals, Inc. High concentration formulations of anti-C5 antibodies
CA2832136C (en) 2002-09-27 2015-11-17 Xencor Optimized fc variants and methods for their generation
US7361339B2 (en) 2003-01-09 2008-04-22 Alexion Pharmaceuticals, Inc. Methods for reducing morality associated with acute myocardial infarction
US20070292416A1 (en) 2003-06-02 2007-12-20 Alexion Pharmaceuticals, Inc. De-Immunized Anti-Cd3 Antibody
US20070116710A1 (en) * 2004-02-03 2007-05-24 Leonard Bell Methods of treating hemolytic anemia
US20050169921A1 (en) * 2004-02-03 2005-08-04 Leonard Bell Method of treating hemolytic disease
US7803931B2 (en) * 2004-02-12 2010-09-28 Archemix Corp. Aptamer therapeutics useful in the treatment of complement-related disorders
US8685435B2 (en) 2004-04-30 2014-04-01 Allergan, Inc. Extended release biodegradable ocular implants
PT1755674E (pt) * 2004-05-14 2015-02-05 Alexion Pharma Inc Prolongamento da sobrevivência de um aloenxerto por inibição da atividade do complemento
US7919094B2 (en) 2004-06-10 2011-04-05 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
GB0416328D0 (en) 2004-07-21 2004-08-25 Univ Cardiff Use of dry powder compositions for pulmonary delivery
MX2007014428A (es) * 2005-05-19 2008-04-21 Procter & Gamble Metodo para reducir la sepsis o el choque cardiogenico asociado a una lesion del miocardio.
EP1739078A1 (de) * 2005-05-30 2007-01-03 Jerini AG C5a-Rezeptor-Antagonisten
WO2007002571A2 (en) * 2005-06-23 2007-01-04 Alexion Pharmaceuticals, Inc. Use of an anti c5 complement antibody to treat patients with sickle cell disease
EP1893647A2 (en) * 2005-06-23 2008-03-05 MedImmune, Inc. Antibody formulations having optimized aggregation and fragmentation profiles
AU2006283532B2 (en) 2005-08-19 2012-04-26 Abbvie Inc. Dual variable domain immunoglobin and uses thereof
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
GB0518443D0 (en) * 2005-09-09 2005-10-19 Evolutec Ltd Method of treating myasthenia gravis
KR20080048034A (ko) * 2005-09-19 2008-05-30 체에스엘 베링 게엠베하 만성 신장병증 치료용 인자 ｈ 및 이의 제조
FR2894145B1 (fr) * 2005-12-07 2008-10-17 Lab Francais Du Fractionnement Utilisation de facteur h du complement a titre de medicament
PT1988882E (pt) * 2006-03-02 2015-02-17 Alexion Pharma Inc Prolongamento da sobrevivência de um aloenxerto por inibição da atividade do complemento
EP4316465A3 (en) * 2006-03-15 2024-04-24 Alexion Pharmaceuticals, Inc. Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement
US8037880B2 (en) 2006-04-07 2011-10-18 The University Of Western Ontario Dry powder inhaler
AU2006343402A1 (en) * 2006-05-01 2007-11-15 Alexion Pharmaceuticals, Inc. Methods for the treatment of muscular dystrophy associated with dysferlin-deficiency
US20090041764A1 (en) * 2006-10-20 2009-02-12 Alexion Pharmaceuticals, Inc. Methods for the treatment of muscular dystrophy associated with dysferlin-deficiency
JP5332064B2 (ja) * 2007-03-01 2013-11-06 ウェルスタット イムノセラピューティクス， エルエルシー 炎症により特徴付けられる疾患の治療
US20110008343A1 (en) * 2007-06-08 2011-01-13 Lambris John D Method Of Reducing Tissue Loss In Pancreatic Islet Cell Transplantation
DK2328616T3 (en) * 2008-08-05 2015-07-20 Novartis Ag Compositions and Methods for Antibodies to Complement Protein C5
CA2742802C (en) * 2008-11-10 2019-11-26 Alexion Pharmaceuticals, Inc. Methods and compositions for treating complement-associated disorders
US20120022505A1 (en) 2010-07-20 2012-01-26 Bruno Dacquay Closed loop glaucoma drug delivery system

Also Published As

Publication number Publication date
JP2021167362A (ja) 2021-10-21
CN102271703A (zh) 2011-12-07
EP2352517A4 (en) 2013-01-16
US20160355580A1 (en) 2016-12-08
DK2894165T3 (da) 2023-03-20
US20200140531A1 (en) 2020-05-07
JP2016196513A (ja) 2016-11-24
CA2742802A1 (en) 2010-05-14
EP2894165B1 (en) 2023-01-04
EP3974448A1 (en) 2022-03-30
US20170015740A1 (en) 2017-01-19
CN109045296A (zh) 2018-12-21
EP2894166A1 (en) 2015-07-15
EP3101031A1 (en) 2016-12-07
HUE061548T2 (hu) 2023-07-28
CA3035432A1 (en) 2010-05-14
US11807678B2 (en) 2023-11-07
CN104940917A (zh) 2015-09-30
DK2894165T5 (da) 2024-10-14
JP2019203036A (ja) 2019-11-28
EP2352517A1 (en) 2011-08-10
SI2894165T1 (sl) 2023-04-28
JP2015155473A (ja) 2015-08-27
AU2009313203B2 (en) 2015-08-27
US20250092123A1 (en) 2025-03-20
US20120225056A1 (en) 2012-09-06
AU2009313203A1 (en) 2010-05-14
JP2024107240A (ja) 2024-08-08
NZ606825A (en) 2014-10-31
WO2010054403A1 (en) 2010-05-14
JP2018030882A (ja) 2018-03-01
PL2894165T3 (pl) 2023-04-17
JP2012508262A (ja) 2012-04-05
JP2014185174A (ja) 2014-10-02
NZ592786A (en) 2013-02-22
LT2894165T (lt) 2023-03-10
EP3121197A1 (en) 2017-01-25
FI2894165T3 (fi) 2023-03-23
US20170369562A1 (en) 2017-12-28
PT2894165T (pt) 2023-03-17
JP6189895B2 (ja) 2017-08-30
US20160319004A1 (en) 2016-11-03
KR20110094029A (ko) 2011-08-19
NZ614351A (en) 2015-05-29
US9771418B2 (en) 2017-09-26
EP2894165A1 (en) 2015-07-15
US20160355579A1 (en) 2016-12-08
ES2940466T3 (es) 2023-05-08
US9447176B2 (en) 2016-09-20
SMT202300082T1 (it) 2023-05-12
BRPI0921237A2 (pt) 2015-09-22
US20200071391A1 (en) 2020-03-05
CN102271703B (zh) 2015-09-16
JP6223659B2 (ja) 2017-11-01
HRP20230167T1 (hr) 2023-03-31
CA2742802C (en) 2019-11-26

Similar Documents

Publication Publication Date Title
RS64039B1 (sr) Metode i kompozicije za lečenje poremećaja povezanih sa komplementom
SMT201500280B (it) Nuove composizioni per prevenire e/o trattare disturbi da accumulo lisosomiale
DK2796469T3 (da) Hidtil ukendte sammensætninger og fremgangsmåder til behandling af IgE-medierede forstyrrelser
IL258730A (en) Preparations and methods for the treatment of microbial disorders
PT2367561E (pt) Composições e métodos para o tratamento da doença celíaca
BR112012001325A2 (pt) tratamento de distúrbios do fígado com inibidaores de pi3k
EP2170309A4 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT OF DISEASES
PT2300614E (pt) Métodos e composições para tratamento de distúrbios mitocondriais
BR112012004979A2 (pt) composições para o tratamento de semente e métodos
DK2211846T3 (da) Hidtil ukendte tilgange til behandling af CMT- og beslÇgtede lidelser
WO2011049960A9 (en) Compositions and methods for the treatment of sinonasal disorders
EP2309858A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF INFLAMMATORY DISEASES
BRPI0911612A2 (pt) composições e métodos para o tratamento da esclerose múltipla.
BRPI1007929A2 (pt) "métodos e composições para o tratamento de neovascularização".
BRPI0820440A2 (pt) Inibidores aldh-2 no tratamento de desordens psiquiátricas
HK1160598A1 (zh) 治療腎功能紊亂的組合物和方法
PL2205720T3 (pl) Kompozycja do leczenia stwardnienia rozsianego
EP2249789A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF XEROSOMY
BRPI0821026A2 (pt) Derivados de alfa-minoamidas úteis no tratamento de transtornos psiquiátricos
HK1157228A1 (en) Compositions and methods of treating amyloid disease
PL2113254T3 (pl) Kompozycje do leczenia autoimmunologicznego stanu zapalnego
EP2170314A4 (en) METHOD AND COMPOSITIONS FOR TREATING PHENYLKETONURIA
EP2334179A4 (en) AHCY HYDROLASE INHIBITORS FOR THE TREATMENT OF HYPERHOMOCYSTEINEEMIA
GB0808326D0 (en) Compositions and methods for the treatment of fybromyalgia
EP2200627A4 (en) METHOD AND COMPOSITIONS FOR TREATING MELANOMA